JP Morgan Maintains Overweight on Replimune Group, Raises Price Target to $21

Benzinga Newsdesk www.benzinga.com Positive 77.1%

Neg 0% Neu 0% Pos 77.1%

JP Morgan analyst Anupam Rama maintains Replimune Group (NASDAQ:REPL) with a Overweight and raises the price target from $20 to $21.